AYAnton Yu. Yushin

Anton Yu. Yushin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anton Yu. Yushin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Vadim Valerievich Klimontov

    Research Institute of Clinical and Experimental Lymphology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences; Novosibirsk State University

    3 shared publications
  • Anton Ivanovich Korbut

    Research Institute of Clinical and Experimental Lymphology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences

    2 shared publications
  • Julia F. Semenova

    Research Institute of Clinical and Experimental Lymphology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia

    2 shared publications
  • А. Ю. Юшин

    Научно-исследовательский институт клинической и экспериментальной лимфологии — филиал ФГБНУ Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук

    2 shared publications
  • Alexander T. Teplyakov

    Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences

    1 shared publication
  • Elena V. Grakova

    Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences

    1 shared publication

Latest Publications

  • Open Access

    Obesity in Patients with Type 1 Diabetes: Causes and Consequences

    by V. V. Klimontov, A. Yu. Yushin, А. Ю. Юшин

    Obesity in patients with type 1 diabetes (T1D) is an increasingly important problem in diabetology. According to recent studies, the prevalence of overweight and obesity among patients with T1D varies from 15 to 50%. About a quarter of patients with T1D have metabolic syndrome. On the one hand, weight gain in patients with T1D reflects a general population trend. On the other hand, diabetes-related factors such as basal-bolus insulin therapy, chronic insulin overdose, hypoglycemia, and psychological problems associated with the disease can be promoters of weight gain. The relationship between T1D and obesity can be bidirectional. It has been established that overweight and obesity increase the risk of T1D, probably contributing to the autoimmune destruction of beta cells. Individuals with overweight and obesity, compared with patients with normal body weight, more often have insulin resistance, dyslipidemia and require higher doses of insulin to achieve targets of glycemic control. Obesity in individuals with T1D a risk factor for diabetic microvascular complications, arterial hypertension, chronic kidney disease, chronic heart failure, cardiovascular events, non-alcoholic fatty liver disease, and is associated with increased mortality. Therefore, maintaining normal body weight should be considered as an important option in the management of T1D. Education, moderate calorie restriction diet, and physical activity are the basis of the strategy for the prevention and treatment of obesity in individuals with T1D. Glucagon-like peptide-1 agonists, dual agonists of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, sodium-glucose cotransporter 2 inhibitors, and metformin are considered promising therapeutic options; however, data on the efficacy and safety of these drugs in patients with T1D are still limited. Experience in performing bariatric interventions in individuals with T1D and morbid obesity is accumulating. Further research is needed to create programs for the prevention and treatment of obesity in patients with T1D.

  • Open Access

    Overweight and obesity in patients with type 1 diabetes: associations with vascular complications and biomarkers of vascular remodeling

    by V. V. Klimontov, A. Yu. Yushin, Yu. F. Semenova, A. I. Korbut, V. V. Romanov, А. Ю. Юшин

    BACKGROUND: The prevalence of overweight and obesity in patients with type 1 diabetes (T1D) is increasing, which raises the issue of their impact on the development of complications.AIM: to study the associations of overweight and obesity with vascular complications, cardiovascular risk factors and serum levels of vascular remodeling biomarkers in patients with T1D.MATERIALS AND METHODS: The study included 547 patients, including 309 with body mass index (BMI) 2, 155 with BMI 25–29.9 kg/m2, and 83 with BMI ≥30 kg/m2. Insulin sensitivity was assessed by the estimated glucose disposal rate. In the serum of 130 patients and 30 individuals with normal weight and normal glucose tolerance, concentrations of advanced glycation end products (AGEs), endothelin-1, endothelial NO synthase (NOS3), adrenomedullin (ADM), endothelial cell-specific molecule-1 (ESM1), cell adhesion molecules (ICAM-1 and VCAM-1), integrin-associated protein-1 (IAP-1), integrin receptor subunit (ITGB1), heme oxygenase-1 (HO-1), GAS6, decorin, and transforming growth factor β1 (TGF-β1) were determined by ELISA.RESULTS: Obesity in patients with T1D was independently associated with coronary artery disease, myocardial infarction, and chronic heart failure. Overweight was an independent predictor of chronic heart failure only. Patients with BMI ≥25 kg/m2, when compared with those with BMI 2, were older, had a reduced insulin sensitivity and increased levels of triglycerides, LDL-cholesterol, uric acid, and high-sensitivity C-reactive protein. Patients with T1D, as compared with controls, showed a significant increase in serum AGEs, endothelin-1, ICAM-1, VCAM-1, IAP-1, ESM1, HO-1, GAS6, and TGF-β1. Overweight patients, when compared with those with BMI 2, demonstrated higher levels of ICAM-1, IAP-1, ITGB1 and TGF-β1, while obese individuals had increased concentrations of AGEs, IAP-1 and HO-1.CONCLUSION: In patients with T1D, overweight and obesity are associated with vascular complications, their risk factors and biomarkers of vascular remodeling.


  • Open Access

    Course of arterial hypertension during breast cancer chemotherapy with anthracyclines

    by E. N. Berezikova, S. N. Shilov, A. A. Popova, M. N. Neupokoeva, A. T. Teplyakov, E. V. Grakova, К. В. Копьева, V. V. Kalyuzhin, A. Yu. Yushin

    Aim. To study the characteristics of the course of arterial hypertension (AH) and subclinical cardiac damage during breast cancer chemotherapy with doxorubicin.Materials and methods. The study included a total of 27 women with breast cancer (BC) and a history of controlled hypertension who were to receive chemotherapy with anthracyclines. Twelve women had stage 1 hypertension; 15 women had stage 2 hypertension. The patients received dual antihypertensive therapy according to clinical guidelines. All patients underwent echocardiography and 24-hour blood pressure monitoring at baseline, after the last course of chemotherapy, and 12 months after the end of chemotherapy. The control group included 35 women with BC without a history of AH, who also were to receive anthracycline chemotherapy.Results. A significant relationship between pre-existing AH and the development of left ventricular systolic dysfunction 12 months after the completion of chemotherapy (p = 0.01) was found. According to 24-hour blood pressure monitoring, 15 women (55.6%) showed deterioration of blood pressure control after the completion of chemotherapy, which required modification of antihypertensive therapy by adding one more drug to the treatment regimen. At 12 months after the end of chemotherapy, in 13 women, hypertension control was reached with triple antihypertensive therapy. In two women, hypertension became resistant, which required prescription of a fourcomponent antihypertensive regimen.Conclusion. Pre-existing AH plays an essential role in the development of anthracycline-induced cardiotoxicity, despite the quality of blood pressure control. Polychemotherapy with anthracyclines may deteriorate blood pressure control in patients with AH, which requires addition of antihypertensive drugs to the treatment regimen.


  • Open Access

    Glucose Variability in People with Type 1 Diabetes: Associations with Body Weight, Body Composition, and Insulin Sensitivity

    by Julia F. Semenova, Anton Yu. Yushin, Anton I. Korbut, Vadim V. Klimontov

    The prevalence of overweight and obesity increases in people with type 1 diabetes (T1D). However, the impact of fat accumulation on glucose dynamics in T1D is poorly understood. We assessed continuous glucose monitoring (CGM) parameters in patients with T1D depending on their body weight, body composition, and insulin sensitivity. In 547 patients, including 238 overweight/obese individuals, CGM-derived time in range (TIR) and glucose variability (GV) were estimated. Body composition was assessed by DXA. Estimated glucose disposal rate (eGDR) was used as an indicator of insulin sensitivity. Overweight/obese patients, when compared to normal-weight ones, have a lower time below range (TBR) (<3 mmol/L), GV, and experienced fewer episodes of low glucose. In men, lower TIR, higher time above range (TAR), and GV reduction were associated with central adiposity assessed by total, trunk, and android fat mass. In women, gynoid fat mass only was associated with a lower TIR and higher TAR. The eGDR was a positive predictor of TIR and a negative predictor of TAR, TBR, and GV in men and women. In conclusion, adiposity in people with T1D is associated with a lower risk of CGM-confirmed hypoglycemia, higher TAR, and reduced GV. These features of daily glucose dynamics may be mediated by insulin resistance.